Home > Insider Trading > Filing (0001437749-24-022708)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
907654	Arca Biopharma Inc.	ABIO	In Vitro & In Vivo Diagnostic Substances (2835)	363855489

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1274173	Plc Group Henderson Janus	201 Bishopgate London X0 EC2M 3AE		No	No	Yes	No
2030299	Ltd Fund Master Innovation Biotech Henderson Janus	201 Bishopgate London X0 EC2M 3AE		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-07-03	166,042	$3.55	1,648,577	No	4	P	Indirect	By Fund
Common Stock	Acquisiton	2024-07-05	23,326	$3.43	1,671,903	No	4	P	Indirect	By Fund
Common Stock	Acquisiton	2024-07-05	5,000	$3.41	1,676,903	No	4	P	Indirect	By Fund
Common Stock	Acquisiton	2024-07-08	29,892	$3.41	1,706,795	No	4	P	Indirect	By Fund
Common Stock	Acquisiton	2024-07-08	17,600	$3.54	1,724,395	No	4	P	Indirect	By Fund
Common Stock	Acquisiton	2024-07-09	16,917	$3.43	1,741,312	No	4	P	Indirect	By Fund
Common Stock	Acquisiton	2024-07-10	33,500	$3.46	1,774,812	No	4	P	Indirect	By Fund
Common Stock	Acquisiton	2024-07-10	21,963	$3.46	1,796,775	No	4	P	Indirect	By Fund
Common Stock	Acquisiton	2024-07-11	94,537	$3.45	1,891,312	No	4	P	Indirect	By Fund

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Fund
No	4	P	Indirect	By Fund
No	4	P	Indirect	By Fund
No	4	P	Indirect	By Fund
No	4	P	Indirect	By Fund
No	4	P	Indirect	By Fund
No	4	P	Indirect	By Fund
No	4	P	Indirect	By Fund
No	4	P	Indirect	By Fund

Footnotes

The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serves as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.